B
Bull
Bull · 25%CAMP
$1.48
情景价格
$3.800
+0.010 (+0.26%)收盘时
Loading chart…
- High
- 4.070
- Open
- 3.850
- VWAP
- 3.88
- Vol
- 215.20K
- Mkt Cap
- 660.34K
- Low
- 3.780
- Amount
- 835.67K
- EV/EBITDA, TTM
- 8.64
CAMP4 Therapeutics Corporation is a clinical-stage biopharmaceutical company. The Company is focused on the discovery and development of regulatory RNA-based therapeutics with the goal of upregulating gene expression and restoring healthy protein levels to treat a range of genetic diseases. It is leveraging its RAP Platform to advance a pipeline of programs focused on metabolic and central nervous system (CNS) disorders with validated disease biology and potential market opportunities due to the significant unmet need of affected patients. Its lead product candidate, CMP-CPS-001, has the potential to be the first disease-modifying therapy for the treatment of urea cycle disorders. CMP-CPS-001 is designed to improve urea cycle activity by amplifying expression of CPS1, a key enzyme that catalyzes the first step of the urea cycle, by binding to a CPS1-specific regRNA. Its CNS development program, CMP-SYNGAP, is focused on addressing the underlying cause of SYNGAP1-related disorders.
估值指标
The current forward P/E ratio for CalAmp Corp (CAMP) is 0.07, compared to its 5-year average forward P/E of -21.51.
Alphio AI Price Scenarios for CAMP
Scenario prices are the last monthly forecast band of the current year. Probabilities are fixed model weights (25 / 50 / 25), not guarantees.
Whales holding CAMP
事件时间线
资讯
9.508-17NASDAQ.COMCAMP4 Therapeutics Reports Q2 2026 Financial Results and Updates
9.508-04NASDAQ.COMBiotech Stocks Surge with Significant Gains
5.007-01NewsfilterX4 Pharmaceuticals Appoints Kelly Gold to Board of Directors
6.006-16CNBCMajor Wall Street Rating Changes Overview
9.505-08seekingalphaCamp4 Therapeutics Q1 Earnings Report Analysis
CAMP FAQ — answered by Alphio AI
CAMP4 Therapeutics Corporation is a clinical-stage biopharmaceutical company. The Company is focused on the discovery and development of regulatory RNA-based therapeutics with the goal of upregulating gene expression and restoring healthy protein levels to treat a range of genetic diseases. It is leveraging its RAP Platform to advance a pipeline of programs focused on metabolic and central nervous system (CNS) disorders with validated disease biology and potential market opportunities due to the significant unmet need of affected patients. Its lead product candidate, CMP-CPS-001, has the potential to be the first disease-modifying therapy for the treatment of urea cycle disorders. CMP-CPS-001 is designed to improve urea cycle activity by amplifying expression of CPS1, a key enzyme that catalyzes the first step of the urea cycle, by binding to a CPS1-specific regRNA. Its CNS development program, CMP-SYNGAP, is focused on addressing the underlying cause of SYNGAP1-related disorders. It operates in the Technology sector (RADIO & TV BROADCASTING & COMMUNICATIONS EQUIPMENT industry).
本页仅供研究参考，不构成投资建议。模型可能出错。过往表现不代表未来结果。